Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Computer-based simulation modeling to determine ED HIV screening costs

Introducing HIV screenings into the nation's emergency departments (EDs) leaves some doctors worrying about longer wait times, disrupted operations, and possible interference with necessary emergency services. Are their concerns unfounded? New research at the University of Cincinnati will use computer-based simulation modeling to determine how screening for HIV in the emergency department will affect how those departments operate.

21 Nov 2012

Patheon to launch $30 million transferable rights offering

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it will launch a U.S. $30 million transferable rights offering.

19 Nov 2012

KemPharm announces successful Type B meeting with FDA for KP201

KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today a successful Type B meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201.

19 Nov 2012

Certain occupations do increase risk of breast cancer

Is there a link between the risk of breast cancer and the working environment? A study published in BioMed Central's open access journal Environmental Health provides further evidence on this previously neglected research topic, confirming that certain occupations do pose a higher risk of breast cancer than others, particularly those that expose the worker to potential carcinogens and endocrine disrupters.

19 Nov 2012

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen that tricks the immune system into stopping its attack on myelin and halt a model of relapsing remitting multiple sclerosis (MS) in mice, according to new Northwestern Medicine research.

19 Nov 2012

NIH-funded scientists develop new treatment to combat autoimmune disorders in mouse model

In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.

18 Nov 2012

United States Pharmacopeial Convention to host Fifth Bioassay Workshop in Rockville

As a growing number of biologic drugs are treatments of choice for an expanding list of autoimmune disorders, inflammatory diseases, and certain cancers, bioassays play a critical role in establishing the functional integrity and potency of these products.

17 Nov 2012

Thermo Fisher announces opening of new facility in Suzhou, China

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its new facility in Suzhou, China, for the manufacturing of life sciences consumables and equipment. The facility expands the company's global manufacturing footprint and establishes local production capabilities to meet increased customer demand in China and other Asia-Pacific markets.

From Thermo Fisher Scientific Inc. 16 Nov 2012

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

Men with wider variation in sperm length have fertility problems

Perhaps variety is the very spice of life, but as a matter of producing human life, it could be the bane of existence. That's the indication of a new study in the journal Human Reproduction that found men with wider variation in sperm length, particularly in the flagellum, had lower concentrations of sperm that could swim well. Those with more consistently made sperm seemed to have more capable ones.

14 Nov 2012

AspenBio Pharma provides clinical and business update for third quarter 2012

AspenBio Pharma, Inc., an in vitro diagnostic company, today provided a clinical and business update for the third quarter 2012. The Company reported it has started the hospital training phase of its pivotal U.S. clinical study and remains on track to initiate patient enrollment before the end of the year.

13 Nov 2012

RTS,S vaccine candidate can help protect African infants against malaria

International African Vaccinology Conference, Cape Town, South Africa-Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria.

9 Nov 2012

Leica Microsystems and TrueVision® 3D Surgical introduce digital 3D-integrated ophthalmic microscope

Leica Microsystems and TrueVision® 3D Surgical announced today that key components of the TrueVision® 3D intelligent digital visualization and guidance platform have been integrated with select future models of Leica Microsystems’ ophthalmic surgical microscopes and will be marketed under the Leica brand.

8 Nov 2012

New instrument for OINDP characterization from Malvern Instruments to be showcased at DDL23

Malvern Panalytical will showcase the new Morphologi G3-ID particle characterization system at Drug Delivery to the Lungs 23, which takes place from 5 – 7 Dec 2012 in Edinburgh, Scotland.

From Malvern Panalytical 6 Nov 2012

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012